Ularitide could make waves in acute decompensated heart failure market, says analyst

18 February 2016

The fast-tracking of Ularitide, a novel drug for the treatment of acute decompensated heart failure (ADHF), has the potential to bring valuable new therapeutic options to what has long been a stagnant market, according to an analyst with research and consulting firm GlobalData.

Ularitide, a chemically synthesized form of urodilatin developed by Switzerland-based Cardiorentis, is in a Phase III clinical trial to test the drug’s efficacy in ADHF patients. Despite being a small organization, privately-held Cardiorentis anticipates positive top-line results from the investigation, which will be announced at the American College of Cardiology Late-Breaking Clinical Trial Sessions in April.

Elizabeth Hamson, GlobalData’s analyst covering cardiovascular and metabolic disorders, says that while Cardiorentis’ size means the company has limited commercialization experience, it does have the requisite financial backing to make its drug a success.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK